This is the new MLex platform. Existing customers should continue to access MLex here until migrated to the new platform. For any migration queries, please contact Customer Services or your Account Manager.

Killer acquisition concerns highlighted by EU study of pharma sector

( November 28, 2024, 17:42 GMT | Official Statement) -- MLex Summary: A study on killer acquisitions commissioned by the European Commission found 89 pharma deals or partnerships between 2014-18 that led to a drug being discontinued and may have deserved competition scrutiny. The study by Lear, an economic consultancy, notes that the discontinued drugs were "overlapping [and] at a relatively advanced stage of development" in "concentrated" markets and say these features are "potentially consistent with a killer acquisition theory of harm." The study also examined the European Commission's track-record in designing remedies to address killer acquisition concerns and the ease with which it could target such deals using the antitrust tools. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections